Wednesday, March 17, 2010
warfarin anticoagulans
Freek Verheugt on EXPLORE-Xa
"Nearly 500 patients with atrial fibrillation were randomized to three doses of the novel oral direct factor Xa blocker betrixaban for 5 months, or to warfarin. Bleeding and side effects were the lowest with low-dose (40 mg) betrixaban. Betrixaban is cleared completely by the liver and seems to be a promising once-daily Xa blocker. Larger trials are warranted, though."# posted by roodbont @ 2:39 AM 
